Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents

Takayuki Katsuyama, Ken Ei Sada, Minglu Yan, Sonia Zeggar, Sumie Hiramatsu, Yoshia Miyawaki, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Eri Katsuyama, Mariko Takano-Narazaki, Noriko Toyota-Tatebe, Katsue Sunahori-Watanabe, Tomoko Kawabata, Kohei Miyake, Toru Kiguchi, Jun Wada

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: To determine prognostic factors of methotrexate-associated lymphoproliferative disorder (MTX-LPD) and evaluate the efficacy and safety of biological therapy in rheumatoid arthritis (RA) complicated with MTX-LPD. Methods: Thirty RA patients who developed MTX-LPD were investigated in this study. We compared the clinical and laboratory parameters of patients who achieved regression of LPD by MTX withdrawal with those who required chemotherapy and evaluated the clinical course of RA after LPD development. Results: Twenty-three patients (76.7%) achieved regression of LPD by MTX withdrawal. Chemotherapy-free patients had a tendency of shorter RA duration (13.1 vs. 22.0 years, p = 0.108) and higher doses of MTX at LPD diagnosis (8.0 vs. 5.3 mg/w, p = 0.067) than patients who required chemotherapy. A significantly higher positive rate of peripheral blood Epstein–Barr virus (EBV)-DNA was observed in the chemotherapy-free group (9/9 vs. 0/3, p = 0.0002). Of 15 patients that received biological agents after LPD development, 14 patients (93.3%) demonstrated an improved disease activity of RA and persistent remission of LPD, whereas only one patient experienced relapse of LPD during tocilizumab therapy. Conclusions: Peripheral blood EBV-DNA positivity is a potential prognostic marker of better outcome in MTX-LPD. Biological agents could be an option for the treatment of RA patients with MTX-LPD.

Original languageEnglish
Pages (from-to)773-777
Number of pages5
JournalModern Rheumatology
Volume27
Issue number5
DOIs
Publication statusPublished - Sep 3 2017

Keywords

  • Biological therapy
  • Epstein–Barr virus
  • Methotrexate-associated lymphoproliferative disorders
  • Prognostic factors
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents'. Together they form a unique fingerprint.

  • Cite this

    Katsuyama, T., Sada, K. E., Yan, M., Zeggar, S., Hiramatsu, S., Miyawaki, Y., Ohashi, K., Morishita, M., Watanabe, H., Katsuyama, E., Takano-Narazaki, M., Toyota-Tatebe, N., Sunahori-Watanabe, K., Kawabata, T., Miyake, K., Kiguchi, T., & Wada, J. (2017). Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Modern Rheumatology, 27(5), 773-777. https://doi.org/10.1080/14397595.2016.1259714